Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

Angiogram-Derived Functional Tests Pre-TAVI: Simpler, Yes, but Warranted?

Michael O'Riordan

September 21, 2023

News Daily News

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Michael O'Riordan

September 13, 2023

News Daily News

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

Michael O'Riordan

March 31, 2023

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Opinion Editor's Corner

ISCHEMIA Questions? Some Answers From David Maron

Shelley Wood

December 09, 2019

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Daily News

Unknowns Predominate in Variable Clopidogrel Response

January 16, 2013

Advertisement

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Angiogram-Derived Functional Tests Pre-TAVI: Simpler, Yes, but Warranted?

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

ISCHEMIA Questions? Some Answers From David Maron

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Unknowns Predominate in Variable Clopidogrel Response

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content